FDA tells UniQure study data insufficient for brain disorder therapy application
02/03/2026 12:12
March 2 (Reuters) - UniQure UQ1.F said on Monday the U.S. Food and Drug Administration has told the company that its data from an early-to-mid stage trial would not support a marketing application for its brain disorder gene therapy. (Reporting by Puyaan Singh in Bengaluru; Editing by Shilpi Majumdar) ((Puyaan.Singh@thomsonreuters.com;))
Recent news on uniQure
See all newsuniQure tumbles after updated Huntington's disease gene therapy data
UniQure plunges as Huntington's trial data disappoints investors (updated)
uniQure tumbles after updated Huntington's disease gene therapy data
UniQure's Huntington's therapy fails to significantly slow disease progression in trial
uniQure seeks US approval for Huntington's gene therapy after FDA reversal